Maintenance oral immunotherapy is effective at 1 year for reducing peanut allergies in preschoolers.
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
The approval was supported by data from the phase 3 POLYP 1 (N=138) and POLYP 2 (N=127) trials evaluating the efficacy and safety of Xolair in adults with nasal polyps who had an inadequate response to nasal corticosteroids.
The effect of coronavirus disease 2019 (COVID-19) on patients with food allergy and their parents and caregivers is substantial.
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Larger skin flare results in pediatric patients correlated to failing certain oral food challenges, but were not predictive of requiring epinephrine.
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.